Close Menu

NEW YORK – Neurodegenerative disease test development firm CND Life Sciences said on Tuesday it has closed a $2.4 million seed financing round.

HonorHealth, a local health system in the Phoenix area, and other investors participated in the funding, CND said. The financing will go toward the expansion of the company's laboratory operations and acceleration of the sales and marketing efforts of its Syn-One Test for diagnosing neurological disorders such as Parkinson's disease and dementia with Lewy bodies, CND CEO Richard Morello said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.